Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 3Phase 3 1Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 55Neoplasm Metastasis 17Carcinoma, Renal Cell 15Carcinoma, Non-Small-Cell Lung 15Neoplasms 14Pancreatic Neoplasms 11Uveal Melanoma 10Prostatic Neoplasms 10Leukemia, Myeloid, Acute 9Squamous Cell Carcinoma of Head and Neck 7Sarcoma 7Myelodysplastic Syndromes 7Lymphoma 7Lung Neoplasms 7Leukemia, Lymphocytic, Chronic, B-Cell 7Colorectal Neoplasms 7Carcinoma, Hepatocellular 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Carcinoma, Transitional Cell 6Breast Neoplasms 6Triple Negative Breast Neoplasms 5Small Cell Lung Carcinoma 5Recurrence 5Myeloproliferative Disorders 5Multiple Myeloma 5Lymphoma, Non-Hodgkin 5Hematologic Neoplasms 5Glioblastoma 5Urinary Bladder Neoplasms 4Ovarian Neoplasms 4

Interventions

Carboplatin 9pembrolizumab 8Paclitaxel 8Cisplatin 8Radiotherapy, Intensity-Modulated 6Magnetic Resonance Spectroscopy 6Gemcitabine 5fludarabine 4Specimen Handling 4Pemetrexed 4Nivolumab 4Cyclophosphamide 4trebananib 3osimertinib 3liposomal doxorubicin 3Radiotherapy 3Interleukin-2 3Fluorouracil 3Docetaxel 3DNA 3volociximab 2poly ICLC 2lenvatinib 2fludarabine phosphate 2Sorafenib 2Radiosurgery 2Midazolam 2Capecitabine 2Biopsy 2Bevacizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma × Ipilimumab × Clear all
NCT07430202 2026-05-06

A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Not yet recruiting
27 enrolled
Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Carcinoma, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡